Management of acute HCV infection in the era of direct-acting antiviral therapy

[1]  G. Cooke,et al.  Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection , 2018, Journal of viral hepatitis.

[2]  Jean-Michel Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2018. , 2018, Journal of hepatology.

[3]  G. Dore,et al.  Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay , 2018, The Journal of infectious diseases.

[4]  B. Hoen,et al.  Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV , 2018, AIDS.

[5]  C. Boucher,et al.  Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  J. Chhatwal,et al.  Should we treat acute hepatitis C? A decision and cost‐effectiveness analysis , 2018, Hepatology.

[7]  D. Holtzman,et al.  Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014 , 2018, American journal of public health.

[8]  David P. Wilson,et al.  Eliminating hepatitis C virus as a public health threat among HIV‐positive men who have sex with men: a multi‐modelling approach to understand differences in sexual risk behaviour , 2018, Journal of the International AIDS Society.

[9]  H. Hagan,et al.  Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta‐analysis , 2017, Addiction.

[10]  J. Leung,et al.  Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review , 2017, The Lancet. Global health.

[11]  F. Luciani,et al.  Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005‐2014: The HITS‐p study , 2017, Journal of viral hepatitis.

[12]  B. Conway,et al.  Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. , 2017, The International journal on drug policy.

[13]  M. Daniel,et al.  Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection. , 2017, The International journal on drug policy.

[14]  T. Hassanein,et al.  Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. , 2017, Journal of hepatology.

[15]  A. Hogewoning,et al.  Men who have sex with men starting pre-exposure prophylaxis (PrEP) are at risk of HCV infection: evidence from the Amsterdam PrEP study. , 2017, AIDS.

[16]  G. Dore,et al.  Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study. , 2017, The lancet. Gastroenterology & hepatology.

[17]  C. Geurtsvankessel,et al.  HCV antigen instead of RNA testing to diagnose acute HCV in patients treated in the Dutch Acute HCV in HIV Study , 2017, Journal of the International AIDS Society.

[18]  G. Dore,et al.  HCV reinfection incidence among individuals treated for recent infection , 2017, Journal of viral hepatitis.

[19]  J. Rockstroh,et al.  Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. , 2017, The lancet. Gastroenterology & hepatology.

[20]  G. Dore,et al.  HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs , 2017, Current HIV/AIDS Reports.

[21]  M. Hughes,et al.  Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1–Infected Individuals: SWIFT-C , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  J. Pawlotsky,et al.  Multicenter Evaluation of the Cepheid Xpert Hepatitis C Virus Viral Load Assay , 2017, Journal of Clinical Microbiology.

[23]  P. Gustafson,et al.  Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study. , 2017, The lancet. Gastroenterology & hepatology.

[24]  S. Sarin,et al.  Point -of -care testing (POCT) in molecular diagnostics: Performance evaluation of GeneXpert HCV RNA test in diagnosing and monitoring of HCV infection. , 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[25]  Gamal Esmat,et al.  Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.

[26]  Z. Kutalik,et al.  A systematic review and meta‐analysis of HCV clearance , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[27]  G. Lauer,et al.  Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  V. Martel-Laferrière,et al.  Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  D. Dieterich,et al.  Sofosbuvir in the treatment of early HCV infection in HIV-infected men , 2017, HIV clinical trials.

[30]  H. El‐Serag,et al.  Global epidemiology and burden of HCV infection and HCV-related disease , 2017, Nature Reviews Gastroenterology &Hepatology.

[31]  D. D. Des Jarlais,et al.  Prevalence of hepatitis C virus infection among HIV+ men who have sex with men: a systematic review and meta-analysis , 2017, International journal of STD & AIDS.

[32]  A. Mirzazadeh,et al.  Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta‐analysis , 2017, Journal of viral hepatitis.

[33]  A. Howe,et al.  Short‐duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial , 2017, Hepatology.

[34]  H. Stellbrink,et al.  HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. , 2017, Journal of hepatology.

[35]  M. Manns,et al.  Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. , 2017, The Lancet. Infectious diseases.

[36]  G. Lauer,et al.  Phylogenetic analysis of full‐length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study , 2017, Journal of viral hepatitis.

[37]  G. Dore,et al.  Hepatitis C treatment as prevention: evidence, feasibility, and challenges. , 2016, The lancet. Gastroenterology & hepatology.

[38]  A. Lok,et al.  Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. , 2016, Gastroenterology.

[39]  J. Macías,et al.  HCV epidemiology in high-risk groups and the risk of reinfection. , 2016, Journal of hepatology.

[40]  Bing Li,et al.  Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. , 2016, The lancet. Gastroenterology & hepatology.

[41]  H. Hagan,et al.  Spontaneous viral clearance of hepatitis C virus (HCV) infection among people who inject drugs (PWID) and HIV-positive men who have sex with men (HIV+ MSM): a systematic review and meta-analysis , 2016, BMC Infectious Diseases.

[42]  Kathy Petoumenos,et al.  Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE‐C II study , 2016, Hepatology.

[43]  M. Egger,et al.  Hepatitis C virus transmission among human immunodeficiency virus‐infected men who have sex with men: Modeling the effect of behavioral and treatment interventions , 2016, Hepatology.

[44]  E. Shin,et al.  Immune responses and immunopathology in acute and chronic viral hepatitis , 2016, Nature Reviews Immunology.

[45]  M. Hellard,et al.  Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies , 2016, Antiviral therapy.

[46]  J. Cairns,et al.  Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation , 2016, Journal of hepatology.

[47]  P. Easterbrook,et al.  Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. , 2016, The Lancet. Infectious diseases.

[48]  J. Dufour,et al.  Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men. , 2016, Journal of hepatology.

[49]  J. M. Freiman,et al.  Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection , 2016, Annals of Internal Medicine.

[50]  Laetitia Canini,et al.  HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. , 2016, Journal of hepatology.

[51]  J. Feld,et al.  Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights , 2016, Nature Reviews Gastroenterology &Hepatology.

[52]  M. Golden,et al.  Trends in Serosorting and the Association With HIV/STI Risk Over Time Among Men Who Have Sex With Men , 2016, Journal of acquired immune deficiency syndromes.

[53]  J. Pawlotsky,et al.  Performance of rapid diagnostic tests for the detection of antibodies to hepatitis C virus in whole blood collected on dried blood spots , 2016, Journal of viral hepatitis.

[54]  Z. Konopski,et al.  Hepatitis C reinfection after sustained virological response. , 2016, Journal of hepatology.

[55]  M. Hellard,et al.  Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model , 2016, Gut.

[56]  V. Tran,et al.  Hepatitis C treatment as prevention of viral transmission and liver‐related morbidity in persons who inject drugs , 2016, Hepatology.

[57]  A. V. D. Meer.  Faculty Opinions recommendation of Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. , 2016 .

[58]  C. Sabin,et al.  Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  G. Melendez‐Torres,et al.  Illicit drug use and its association with sexual risk behaviour among MSM: more questions than answers? , 2016, Current opinion in infectious diseases.

[60]  R. Riley,et al.  Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[61]  H. Hagan,et al.  Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. , 2016, The Cochrane database of systematic reviews.

[62]  Sheena McCormack,et al.  Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial , 2016, The Lancet.

[63]  T. O'Brien,et al.  No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL , 2016, Hepatology.

[64]  T. Asselah,et al.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. , 2015, The New England journal of medicine.

[65]  David Thompson,et al.  On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. , 2015, The New England journal of medicine.

[66]  D. Y. Kim,et al.  The present and future disease burden of hepatitis C virus infections with today's treatment paradigm – volume 3 , 2015, Journal of viral hepatitis.

[67]  D. De Angelis,et al.  Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence , 2015, Current opinion in infectious diseases.

[68]  A. Mocroft,et al.  Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected? , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[69]  H. Hagan,et al.  Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men , 2015, AIDS.

[70]  L. Real,et al.  Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C. , 2015, The Journal of infection.

[71]  M. Alavi,et al.  Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. , 2015, The International journal on drug policy.

[72]  M. Hellard,et al.  Recommendations for the management of hepatitis C virus infection among people who inject drugs. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[73]  M. Aloysius,et al.  Sofosbuvir and Ledipasvir in Attainment of SVR12 in Sickle Cell Disease (SCD) Sub-population With Chronic Hepatitis C (CHC): A Single-Center, Prospective, Open-Label Clinical Pilot Stud: SLASH C Trial: 2198 , 2015 .

[74]  P. Messa,et al.  Transmission of Hepatitis C Virus in Dialysis Units: A Systematic Review of Reports on Outbreaks , 2015, The International journal of artificial organs.

[75]  K. Chayama,et al.  Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis , 2015, Hepatology.

[76]  J. Feld,et al.  Hepatitis C virus infection , 2015, Canadian Medical Association Journal.

[77]  G. Dore,et al.  Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States , 2015, Annals of Internal Medicine.

[78]  Alan S. Perelson,et al.  Modelling hepatitis C therapy—predicting effects of treatment , 2015, Nature Reviews Gastroenterology &Hepatology.

[79]  S. Braunstein,et al.  Factors Associated With Hepatitis C Infection Among HIV-Infected Men Who Have Sex With Men With No Reported Injection Drug Use in New York City, 2000–2010 , 2015, Sexually transmitted diseases.

[80]  M. Nelson,et al.  Acute hepatitis C infection in HIV‐negative men who have sex with men , 2015, Journal of viral hepatitis.

[81]  John W. Ward,et al.  Increases in Hepatitis C Virus Infection Related to Injection Drug Use Among Persons Aged ≤30 Years — Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012 , 2015, MMWR. Morbidity and mortality weekly report.

[82]  G. Hart,et al.  Sex, drugs and smart phone applications: findings from semistructured interviews with men who have sex with men diagnosed with Shigella flexneri 3a in England and Wales , 2015, Sexually Transmitted Infections.

[83]  K. Kabeya,et al.  Risk Factors for HCV Acquisition Among HIV-Positive MSM in Belgium , 2015, Journal of acquired immune deficiency syndromes.

[84]  P. Bernillon,et al.  Sexual and prevention practices in men who have sex with men in the era of combination HIV prevention: results from the Presse Gays et Lesbiennes survey, France, 2011. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[85]  M. Hellard,et al.  Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study , 2015, PloS one.

[86]  Peter Vickerman,et al.  Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data , 2015, Journal of The Royal Society Interface.

[87]  C. B. Hare,et al.  Incident Hepatitis C Virus Infections Among Users of HIV Preexposure Prophylaxis in a Clinical Practice Setting. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[88]  P. Coffin,et al.  Novel Interventions to Prevent HIV and HCV Among Persons Who Inject Drugs , 2015, Current HIV/AIDS Reports.

[89]  F. Cresswell,et al.  Hepatitis C core antigen testing: a reliable, quick, and potentially cost-effective alternative to hepatitis C polymerase chain reaction in diagnosing acute hepatitis C virus infection. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[90]  Pierre-Marie Girard,et al.  Prevalence and behavioural risks for HIV and HCV infections in a population of drug users of Dakar, Senegal: the ANRS 12243 UDSEN study , 2015, Journal of the International AIDS Society.

[91]  M. Abdel-hamid,et al.  Hepatitis C virus acquisition among Egyptians: analysis of a 10‐year surveillance of acute hepatitis C , 2015, Tropical medicine & international health : TM & IH.

[92]  M. Leshno,et al.  The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm – volume 2 , 2015, Journal of viral hepatitis.

[93]  P. Messa,et al.  Transmission of Hepatitis B Virus in Dialysis Units: A Systematic Review of Reports on Outbreaks , 2015, The International journal of artificial organs.

[94]  J. del Romero,et al.  Incidence of Hepatitis C Virus (HCV) in a Multicenter Cohort of HIV-Positive Patients in Spain 2004–2011: Increasing Rates of HCV Diagnosis but Not of HCV Seroconversions , 2014, PloS one.

[95]  R. Geskus,et al.  Hepatitis C virus (HCV) antibody dynamics following acute HCV infection and reinfection among HIV-infected men who have sex with men. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[96]  J. Hahn,et al.  Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. , 2014, JAMA internal medicine.

[97]  B. Song,et al.  Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection , 2014, Clinical and molecular hepatology.

[98]  Julio S. G. Montaner,et al.  The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. , 2014, Addiction.

[99]  P. Pattison,et al.  The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs , 2014, Hepatology.

[100]  D. De Angelis,et al.  HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact , 2014, Journal of viral hepatitis.

[101]  J. Kaldor,et al.  Dynamics of HCV RNA levels during acute hepatitis C virus infection , 2014, Journal of medical virology.

[102]  F. Luciani,et al.  A prospective study of hepatitis C incidence in Australian prisoners. , 2014, Addiction.

[103]  G. Dore,et al.  Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS‐c study , 2014, The Medical journal of Australia.

[104]  N. Lennox,et al.  Incidence and correlates of hepatitis C virus infection in a large cohort of prisoners who have injected drugs , 2014, BMC Public Health.

[105]  S. Hutchinson,et al.  Rapid Decline in HCV Incidence among People Who Inject Drugs Associated with National Scale-Up in Coverage of a Combination of Harm Reduction Interventions , 2014, PloS one.

[106]  Janet J. Hamilton,et al.  Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[107]  J. Hahn,et al.  Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs , 2014, BMC Public Health.

[108]  L. Valiquette,et al.  Evolution of the Global Burden of Viral Infections from Unsafe Medical Injections, 2000–2010 , 2014, PloS one.

[109]  Julio S. G. Montaner,et al.  Declining Incidence of Hepatitis C Virus Infection among People Who Inject Drugs in a Canadian Setting, 1996-2012 , 2014, PloS one.

[110]  E. Sagnelli,et al.  Acute hepatitis C: A 24‐week course of pegylated interferon alpha‐2b versus a 12‐week course of pegylated interferon alpha‐2b alone or with ribavirin , 2014, Hepatology.

[111]  Robert Herring,et al.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. , 2014, The New England journal of medicine.

[112]  J. Hahn,et al.  Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: a prospective analysis from the UFO Study cohort , 2014, BMJ Open.

[113]  G. Esmat,et al.  The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm , 2014, Journal of viral hepatitis.

[114]  J. P. Davis,et al.  Rapid Hepatitis C Testing Among Persons at Increased Risk for Infection — Wisconsin, 2012–2013 , 2014, MMWR. Morbidity and mortality weekly report.

[115]  M. Abrahamowicz,et al.  Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[116]  V. Lee,et al.  Should we offer routine hepatitis C antibody testing in men who have sex with men? , 2014, Journal of the International AIDS Society.

[117]  S. Oka,et al.  Incidence and Risk Factors for Incident Hepatitis C Infection Among Men Who Have Sex With Men With HIV-1 Infection in a Large Urban HIV Clinic in Tokyo , 2014, Journal of acquired immune deficiency syndromes.

[118]  B. Rehermann,et al.  Immune responses to HCV and other hepatitis viruses. , 2014, Immunity.

[119]  G. Lauer,et al.  The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection , 2014, Hepatology.

[120]  V. Wong,et al.  Targeted hepatitis C screening among ex‐injection drug users in the community , 2014, Journal of gastroenterology and hepatology.

[121]  M. Hellard,et al.  High Rates of Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection in People Who Inject Drugs: A Prospective Cohort Study , 2013, PloS one.

[122]  B. Gazzard,et al.  Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM , 2013, AIDS.

[123]  J. Rich,et al.  Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta‐analysis , 2013, Hepatology.

[124]  V. Moyer,et al.  Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement , 2013, Annals of Internal Medicine.

[125]  G. Dore,et al.  Epidemiology and natural history of HCV infection , 2013, Nature Reviews Gastroenterology &Hepatology.

[126]  M. Hellard,et al.  Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals , 2013, Hepatology.

[127]  P. Bruggmann,et al.  Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[128]  P. Vickerman,et al.  Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[129]  M. Hellard,et al.  Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[130]  P. Vickerman,et al.  Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons , 2013, BMJ Open.

[131]  R. Detels,et al.  Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[132]  M. Manns,et al.  Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. , 2013, The Lancet. Infectious diseases.

[133]  D. Webster,et al.  Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and Ribavirin , 2013, International journal of STD & AIDS.

[134]  G. Lauer,et al.  A simple strategy to identify acute hepatitis C virus infection among newly incarcerated injection drug users , 2013, Hepatology.

[135]  G. Dore,et al.  Case definitions for acute hepatitis C virus infection: a systematic review. , 2012, Journal of hepatology.

[136]  Ning Wang,et al.  Incidence of hepatitis C virus infection in patients on hemodialysis: A systematic review and meta‐analysis , 2012, Hemodialysis international. International Symposium on Home Hemodialysis.

[137]  Rosanna Peeling,et al.  Accuracy of Rapid and Point-of-Care Screening Tests for Hepatitis C , 2012, Annals of Internal Medicine.

[138]  S. Hutchinson,et al.  Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland. , 2012, The International journal on drug policy.

[139]  J. Álamo-Martínez,et al.  Spontaneous clearance of HCV in HIV-hepatitis C virus coinfected liver transplant patients: prospective study. , 2012, Transplantation proceedings.

[140]  L. Terracciano,et al.  Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. , 2012, Gastroenterology.

[141]  H. Günthard,et al.  Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[142]  M. Schechter,et al.  The Cedar Project: high incidence of HCV infections in a longitudinal study of young Aboriginal people who use drugs in two Canadian cities , 2012, BMC Public Health.

[143]  N. Pai,et al.  Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review , 2012, Sexually Transmitted Infections.

[144]  S. Kamili,et al.  Laboratory diagnostics for hepatitis C virus infection. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[145]  R. Garfein,et al.  Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[146]  D. D. Des Jarlais,et al.  Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment. , 2012, Addiction.

[147]  S. Ray,et al.  Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution , 2012, Hepatology.

[148]  M. Hellard,et al.  The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. , 2012, The Journal of infectious diseases.

[149]  J. Kaldor,et al.  Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection , 2012, Hepatology.

[150]  Todd M. Allen,et al.  Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence , 2012, The Journal of experimental medicine.

[151]  Hsin-Yun Sun,et al.  Recent Hepatitis C Virus Infections in HIV-Infected Patients in Taiwan: Incidence and Risk Factors , 2011, Journal of Clinical Microbiology.

[152]  N. Garrett,et al.  Successful treatment of acute hepatitis C virus in HIV positive patients using the European AIDS Treatment Network guidelines for treatment duration. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[153]  B. Grady,et al.  Female Sex and IL28B, a Synergism for Spontaneous Viral Clearance in Hepatitis C Virus (HCV) Seroconverters from a Community-Based Cohort , 2011, PloS one.

[154]  J. V. D. van der Meer,et al.  Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM , 2011, AIDS.

[155]  J. Parry,et al.  The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. , 2011, Addiction.

[156]  K. Konty,et al.  Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations. , 2011, American journal of public health.

[157]  T. Finlayson,et al.  Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[158]  P. Klenerman,et al.  The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals , 2011, The Journal of general virology.

[159]  R. Garfein,et al.  Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus. , 2011, The Journal of infectious diseases.

[160]  Rowena A. Bull,et al.  Sequential Bottlenecks Drive Viral Evolution in Early Acute Hepatitis C Virus Infection , 2011, PLoS pathogens.

[161]  Louisa Degenhardt,et al.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews , 2011, The Lancet.

[162]  D. D. Des Jarlais,et al.  Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject Drugs , 2011 .

[163]  L. Rostaing,et al.  Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[164]  Alan S. Perelson,et al.  Second‐phase hepatitis C virus RNA decline during telaprevir‐based therapy increases with drug effectiveness: Implications for treatment duration , 2011, Hepatology.

[165]  M. Fisher.  Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. , 2011, AIDS.

[166]  J. Hocking,et al.  Incidence of Hepatitis-C among HIV infected men who have sex with men (MSM) attending a sexual health service: a cohort study , 2011, BMC infectious diseases.

[167]  M. Vogel,et al.  Acute hepatitis C infection in HIV-positive patients , 2011, Current opinion in infectious diseases.

[168]  Joseph Eliahoo,et al.  Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men , 2010, Gut.

[169]  G. Dore,et al.  Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection , 2010, Journal of viral hepatitis.

[170]  R. Weber,et al.  Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[171]  K. Shianna,et al.  A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. , 2010, Gastroenterology.

[172]  J. Kaldor,et al.  Potential role for Interleukin‐28B genotype in treatment decision‐making in recent hepatitis C virus infection , 2010, Hepatology.

[173]  William J. Kowalczyk,et al.  Preexposure Prophylaxis and Predicted Condom Use Among High-Risk Men Who Have Sex With Men , 2010, Journal of acquired immune deficiency syndromes.

[174]  T. Rhodes,et al.  Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed , 2010, The Lancet.

[175]  R. Chung,et al.  Early treatment improves outcomes in acute hepatitis C virus infection: a meta‐analysis , 2010, Journal of viral hepatitis.

[176]  M. Clatts,et al.  Prevalence and Incidence of HCV Infection among Vietnam Heroin Users with Recent Onset of Injection , 2010, Journal of Urban Health.

[177]  J. Kaldor,et al.  Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia , 2009, Sexually Transmitted Infections.

[178]  David B. Goldstein,et al.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus , 2009, Nature.

[179]  L. Avanesyan,et al.  Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. , 2009, The Journal of infectious diseases.

[180]  R. Chung,et al.  Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[181]  Martin Fisher,et al.  Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. , 2009, Gastroenterology.

[182]  P. Marotta,et al.  Spontaneous clearance of hepatitis C after liver and renal transplantation. , 2009, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[183]  E. Thomson,et al.  Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV , 2009, AIDS.

[184]  D. D. Des Jarlais,et al.  Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. , 2008, American journal of epidemiology.

[185]  A. Mocroft,et al.  Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. , 2008, The Journal of infectious diseases.

[186]  T. Nichols,et al.  Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial , 2008, Journal of viral hepatitis.

[187]  E. Scott,et al.  Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. , 2007, The Journal of infectious diseases.

[188]  P. Klenerman,et al.  Tracking Virus-Specific CD4+ T Cells during and after Acute Hepatitis C Virus Infection , 2007, PloS one.

[189]  Anne M Johnson,et al.  Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours , 2007, AIDS.

[190]  G. Alexander,et al.  Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type? , 2007, Journal of viral hepatitis.

[191]  B. Berkhout,et al.  Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users , 2007, European Journal of Epidemiology.

[192]  Rohan Jayasuriya,et al.  Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. , 2006, Addiction.

[193]  F. D. De Rosa,et al.  Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C. , 2006, The Journal of antimicrobial chemotherapy.

[194]  M. Manns,et al.  Early monotherapy with pegylated interferon alpha‐2b for acute hepatitis C infection: The HEP‐NET acute‐HCV‐II study , 2006, Hepatology.

[195]  J. Kaldor,et al.  Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies , 2006, Journal of viral hepatitis.

[196]  J. Goedert,et al.  Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. , 2005, Blood.

[197]  S. Ray,et al.  Humoral immune response in acute hepatitis C virus infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[198]  C. Walker,et al.  Adaptive immune responses in acute and chronic hepatitis C virus infection , 2005, Nature.

[199]  S. Polywka,et al.  Prolonged Time until Seroconversion among Hemodialysis Patients: The Need for HCV PCR , 2005, Intervirology.

[200]  L. Gambotti,et al.  Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. , 2005, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[201]  T. Santantonio,et al.  Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. , 2005, Journal of hepatology.

[202]  H. Van Vlierberghe,et al.  Treatment of acute hepatitis C with interferon α‐2b: early initiation of treatment is the most effective predictive factor of sustained viral response , 2004, Alimentary pharmacology & therapeutics.

[203]  H. Nomura,et al.  Short‐term interferon‐alfa therapy for acute hepatitis C: A randomized controlled trial , 2004, Hepatology.

[204]  A. Moss,et al.  Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO study) , 2003, Journal of Urban Health.

[205]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[206]  C. Trautwein,et al.  Treatment of acute hepatitis C with interferon alfa-2b. , 2001, The New England journal of medicine.

[207]  O. Kalinina,et al.  Shift in predominating subtype of HCV from 1b to 3a in St. Petersburg mediated by increase in injecting drug use * , 2001, Journal of medical virology.

[208]  R A Coutinho,et al.  Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection , 2001, AIDS.

[209]  T. Wright,et al.  Acute hepatitis C , 2001, Hepatology.

[210]  D. Vlahov,et al.  The natural history of hepatitis C virus infection: host, viral, and environmental factors. , 2000, JAMA.

[211]  D. Vlahov,et al.  Persistence of viremia and the importance of long‐term follow‐up after acute hepatitis C infection , 1999, Hepatology.

[212]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[213]  J. Preiksaitis,et al.  Serologic responses to hepatitis C virus in solid organ transplant recipients. , 1997, Transplantation.

[214]  D. Holland,et al.  Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[215]  A. Hogewoning,et al.  Men who have sex with men starting pre-exposure prophylaxis (PrEP) are at risk of HCV infection: evidence from the Amsterdam PrEP study. , 2017, AIDS.

[216]  M. Carrieri,et al.  Innovative community-based educational face-to-face intervention to reduce HIV, hepatitis C virus and other blood-borne infectious risks in difficult-to-reach people who inject drugs: results from the ANRS-AERLI intervention study. , 2016, Addiction.

[217]  M. Egger,et al.  Hepatitis C virus transmission among HIV-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions , 2016 .

[218]  Robert S. Brown,et al.  Sofosbuvir and Ledipasvir in Attainment of SVR12 in Sickle Cell Disease (SCD) Sub-Population with Chronic Hepatitis C (CHC) a Single Center Prospective Open Label Clinical Pilot Study – Slash C Trial , 2016 .

[219]  J. Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2015. , 2015, Journal of hepatology.

[220]  William M. Lee,et al.  Interferon Alfa-2 b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C , 2015 .

[221]  JE MegíasVericat.  Patterns of Hepatitis C Virus RNA Levels during Acute Infection : The InC 3 Study , 2015 .

[222]  M. Thursz,et al.  HCV transmission in industrialized countries and resource-constrained areas , 2014, Nature Reviews Gastroenterology &Hepatology.

[223]  A. Pharris,et al.  Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. , 2014, The International journal on drug policy.

[224]  D. Pasta.  Hepatitis C virus acquisition among Egyptians : analysis of a 10-year surveillance of acute hepatitis , 2014 .

[225]  Atlanta,et al.  Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men--New York City, 2005-2010. , 2011, MMWR. Morbidity and mortality weekly report.

[226]  J. Kaldor,et al.  Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. , 2010, Gastroenterology.

[227]  F. D. De Rosa,et al.  A short course of pegylated interferon-alpha in acute HCV hepatitis. , 2007, Journal of viral hepatitis.

[228]  J. McCormick,et al.  Unsafe injections and the transmission of hepatitis B and C in a periurban community in Pakistan. , 2000, Bulletin of the World Health Organization.